FOLH1 and prostate carcinoma: Additionally, Lava Therapeutics, based in Philadelphia, Pennsylvania and the Netherlands, has developed an anti-PSMA (prostate-specific membrane antigen) Vδ2 T cell for combating metastatic castration-resistant prostate cancer [222].